AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8838168 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal distance adjustments in relation to the standard distance.
Number of subjects: 8
Study 1468285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (450 mg/day)
Number of subjects: 95
Study 1468285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 95
Study 1468285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 6331138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cronassial (20 mg daily intramuscularly for 6 weeks)
Number of subjects: 26
Study 6331138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6331138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cronassial
Number of subjects: 26
Study 30466148 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive-behavioral intervention for suicidal ideation
Number of subjects: 418
Study 29517983 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-arm soft fiberglass cast (Group B)
Number of subjects: 100
Study 29517983 — intervention group
Group type: COMPARATOR
Intervention: Long-arm traditional fiberglass (hard) cast (Group A)
Number of subjects: 100
Study 27217287 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive exercise and education programme
Number of subjects: 1482
Study 27217287 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 1482
Study 25475245 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised self‐management support for patients and feedback on use of evidence‐based HF therapies (EBT) to physicians.
Number of subjects: 33
Study 25475245 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised feedback on adherence to EBT for physicians.
Number of subjects: 33
Study 25475245 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education, support, and self‐management training for diet and medication adherence by a trained nurse through 11 interactive sessions over a 4‐month period.
Number of subjects: 33
Study 25475245 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence monitoring using electronic pill cap and Morisky Medication Adherence Scale (MMAS).
Number of subjects: 33
Study 22532849 — intervention group
Group type: EXPERIMENTAL
Intervention: tCBT + EAP
Number of subjects: 118
Study 22532849 — intervention group
Group type: COMPARATOR
Intervention: EAP alone
Number of subjects: 118
Study 20637971 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 10 mg single dose
Number of subjects: 32
Study 20637971 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 5 mg multiple doses
Number of subjects: 32
Study 20637971 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 10 mg multiple doses
Number of subjects: 32
Study 20637971 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin single doses (1, 2.5, 5, 10 mg)
Number of subjects: 32
Study 20637971 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin multiple doses (2.5, 5, 10 mg)
Number of subjects: 32
Study 20637971 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin (various doses)
Number of subjects: 32
Study 18793423 — intervention group
Group type: EXPERIMENTAL
Intervention: NOCOMIT-J multimodal community-based suicide prevention program
Number of subjects: 2120000
Study 18793423 — intervention group
Group type: COMPARATOR
Intervention: Control regions (not specified)
Number of subjects: 2120000
Study 15910155 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthur (children's TV program)
Number of subjects: 108
Study 15910155 — intervention group
Group type: COMPARATOR
Intervention: Between the Lions (control group)
Number of subjects: 108
Study 11952447 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 0 (modified supine position immediately after spinal injection)
Number of subjects: 98
Study 11952447 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (sitting position for 3 min before modified supine position)
Number of subjects: 98
Study 11952447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study 9812410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF) - 80.5 Gy/70 fractions/7 weeks (2 fractions x 1.15 Gy/day)
Number of subjects: 1867
Study 9812410 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 72 Gy/45 fractions/5 weeks
Number of subjects: 1867
Study 9812410 — intervention group
Group type: COMPARATOR
Intervention: Classical fractionation (CF) - 70 Gy/35 fractions/7 weeks
Number of subjects: 1867
Study 8592998 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and dose adjustments of co-trimoxazole (5 mg/kg trimethoprim and 25 mg/kg sulfamethoxazole every 6 h for 2 days, then every 8 h for 21 days)
Number of subjects: 40
Study 8592998 — intervention group
Group type: COMPARATOR
Intervention: Standard co-trimoxazole therapy without monitoring (5 mg/kg trimethoprim and 25 mg/kg sulfamethoxazole every 6 h for 2 days, then every 8 h for 21 days)
Number of subjects: 40
Study 8592998 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (group A)
Number of subjects: 40
Study 8592998 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 40
Study 2650941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 300 mg daily for one week
Number of subjects: 12
Study 368306 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent aqueous phenylephrine
Number of subjects: 48
Study 368306 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent viscous phenylephrine
Number of subjects: 48
Study 368306 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 percent solution (double blind study)
Number of subjects: 48
Study 368306 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent cyclopentolate
Number of subjects: 48
Study 368306 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent tropicamide
Number of subjects: 48
Study 368306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of drugs (protocol at United Hospitals Medical Center)
Number of subjects: 48
Study 31410514 — intervention group
Group type: EXPERIMENTAL
Intervention: Protector™ Laryngeal Mask Airway (LMA)
Number of subjects: 78
Study 31410514 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 78
Study 30103692 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of an ACP-guideline with training and supervision of project teams and staff for 12 months.
Number of subjects: 0
Study 26798083 — intervention group
Group type: EXPERIMENTAL
Intervention: 32G needle
Number of subjects: 0
Study 26798083 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° needle insertion angle
Number of subjects: 0
Study 26798083 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait times of minimum 3 seconds
Number of subjects: 0
Study 26798083 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections in the abdomen
Number of subjects: 0
Study 26798083 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection volume up to 800 µL
Number of subjects: 0
Study 26798083 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin needle
Number of subjects: 0
Study 24561752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hct strategy 34.5%-39.0% (mid)
Number of subjects: 22474
Study 24561752 — intervention group
Group type: COMPARATOR
Intervention: Hct strategy 30.0%-34.5% (low)
Number of subjects: 22474
Study 21792215 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate
Number of subjects: 11
Study 21792215 — intervention group
Group type: COMPARATOR
Intervention: Alpha-lactalbumin, whey isolate, caseinoglycomacropeptide
Number of subjects: 11
Study 19281585 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone daily for three months
Number of subjects: 40
Study 19281585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17229243 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole (IR-OME)
Number of subjects: 54
Study 15580149 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 15580149 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 12001978 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to increase soluble fibre intake to 8.0 g day(‐1) (fruit, vegetables and oats)
Number of subjects: 753
Study 9174231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle feeding
Number of subjects: 30
Study 9174231 — intervention group
Group type: COMPARATOR
Intervention: Bolus gavage feeding
Number of subjects: 30
Study 9174231 — intervention group
Group type: COMPARATOR
Intervention: Slow gavage feeding
Number of subjects: 30
Study 7892424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 40%
Number of subjects: 12
Study 7892424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 10%
Number of subjects: 12
Study 7892424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 5%
Number of subjects: 12
Study 7892424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0%)
Number of subjects: 12
Study 3228817 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 24
Study 3228817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29485676 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 164
Study 29485676 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 164
Study 29485676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (PFI and control)
Number of subjects: 164
Study 27804310 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone plus 400 μg misoprostol per vaginally concurrently (group A)
Number of subjects: 200
Study 27804310 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol administered after 48 hours (group B)
Number of subjects: 200
Study 25631171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional barbed sutures
Number of subjects: 50
Study 25631171 — intervention group
Group type: COMPARATOR
Intervention: Standard sutures
Number of subjects: 50
Study 24080137 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the My Trauma Recovery (CMTR) website intervention
Number of subjects: 183
Study 21169226 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (1200 mg/d)
Number of subjects: 12
Study 18460568 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (two dose levels)
Number of subjects: 0
Study 18460568 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (800 mum of the main metabolite)
Number of subjects: 0
Study 18460568 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (200 mum of 2-hydroxy-4-trifluoromethylbenzoic acid)
Number of subjects: 0
Study 18460568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17290957 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention to prevent workplace violence
Number of subjects: 0
Study 17290957 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and post-intervention survey
Number of subjects: 0
Study 14649507 — intervention group
Group type: EXPERIMENTAL
Intervention: Horsechestnut intervention
Number of subjects: 0
Study 14649507 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to overcome barriers
Number of subjects: 0
Study 10715040 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 508A-enhanced Doppler US
Number of subjects: 198
Study 10715040 — intervention group
Group type: COMPARATOR
Intervention: Nonenhanced Doppler US
Number of subjects: 198
Study 10715040 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 508A
Number of subjects: 198
Study 8873586 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin 100 mg once daily by subcutaneous route (36 patients)
Number of subjects: 100
Study 8873586 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin 100 mg twice a day by subcutaneous route (33 patients)
Number of subjects: 100
Study 8873586 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin 200 mg once daily by intramuscular route (31 patients)
Number of subjects: 100
Study 8156369 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal resection rectopexy and pelvic floor repair
Number of subjects: 20
Study 8156369 — intervention group
Group type: COMPARATOR
Intervention: Perineal rectosigmoidectomy and pelvic floor repair
Number of subjects: 20
Study 2895125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 75 mg bid
Number of subjects: 6
Study 2895125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 6
Study 2895125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid
Number of subjects: 6
Study 2895125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg qid
Number of subjects: 6
Study 2895125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29759105 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian breakfast foods (medium to high GI)
Number of subjects: 19
Study 29759105 — intervention group
Group type: EXPERIMENTAL
Intervention: Western breakfast foods (low GI)
Number of subjects: 19
Study 29759105 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of GI values with dietary components
Number of subjects: 19
Study 28399054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination during pregnancy
Number of subjects: 0
Study 28399054 — intervention group
Group type: COMPARATOR
Intervention: Control group (not vaccinated with Tdap during pregnancy)
Number of subjects: 0
Study 24725308 — intervention group
Group type: EXPERIMENTAL
Intervention: Care transition intervention including pre-discharge education and post-discharge telephone nurse coaching with home telemonitoring.
Number of subjects: 1500
Study 22960196 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion [2.0 pmol kg(‐1) min(‐1) for 240 min]
Number of subjects: 17
Study 22960196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19952762 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1447295 A allele
Number of subjects: 3822
Study 19952762 — intervention group
Group type: EXPERIMENTAL
Intervention: DG8S737 -8 allele
Number of subjects: 3822
Study 19952762 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1447295 A allele in familial prostate cancer
Number of subjects: 3822
Study 19952762 — intervention group
Group type: EXPERIMENTAL
Intervention: DG8S737 -8 allele in familial prostate cancer
Number of subjects: 3822
Study 19952762 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1447295 A allele for aggressive tumours (Gleason score 8 or more)
Number of subjects: 3822
Study 19952762 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1447295 A allele for tumours with Gleason score 7 and below
Number of subjects: 3822
Study 18001246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-tenon triamcinolone acetonide (STA) injection
Number of subjects: 0
Study 16250568 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain (Biora) combined with surgical treatment (SPP flap)
Number of subjects: 153
Study 16250568 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone (SPP)
Number of subjects: 153
Study 12404673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) infusion
Number of subjects: 24
Study 12404673 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study 9803700 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating schedule (n = 20)
Number of subjects: 59
Study 9803700 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating schedule with start-up bonuses (n = 20)
Number of subjects: 59
Study 9803700 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent schedule (n = 19)
Number of subjects: 59
Study 9803700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contingent interventions (escalating schedule and escalating schedule with start-up bonuses)
Number of subjects: 59
Study 7975833 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1LAV gp160 live recombinant vaccinia virus priming followed by a booster injection with a baculovirus‐expressed HIV‐1LAV recombinant gp160 candidate vaccine
Number of subjects: 12
Study 2656263 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 2656263 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study 29886135 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise (MIE)
Number of subjects: 94
Study 29886135 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise (HIE)
Number of subjects: 94
Study 29886135 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 94
Study 29033099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m2 IV every 21 days) plus prednisone (10 mg daily) with custirsen (640 mg IV on days 1, 8, and 15, plus three previous loading doses)
Number of subjects: 635
Study 29033099 — intervention group
Group type: COMPARATOR
Intervention: Cabazitaxel (25 mg/m2 IV every 21 days) plus prednisone (10 mg daily)
Number of subjects: 635
Study 29033099 — intervention group
Group type: EXPERIMENTAL
Intervention: Custirsen group
Number of subjects: 635
Study 29033099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 635
Study 25207707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexmedetomidine (BvD group)
Number of subjects: 90
Study 25207707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl (BvF group)
Number of subjects: 90
Study 25207707 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (Bv group)
Number of subjects: 90
Study 23436098 — intervention group
Group type: EXPERIMENTAL
Intervention: INVEST
Number of subjects: 10
Study 21505304 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Conservation (DC) arm
Number of subjects: 200
Study 21505304 — intervention group
Group type: COMPARATOR
Intervention: Viral Suppression (VS) arm
Number of subjects: 200
Study 18332641 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine skin cultures
Number of subjects: 497
Study 17256437 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN) for 7 days perioperatively
Number of subjects: 27
Study 17256437 — intervention group
Group type: COMPARATOR
Intervention: Standard care (oral diet reintroduction on the fourth postoperative day)
Number of subjects: 27
Study 12939440 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 4
Study 12939440 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 4
Study 10862159 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride nebulized solution three times daily for 6 months
Number of subjects: 137
Study 10862159 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulized solution three times daily for 6 months
Number of subjects: 137
Study 9112877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise rehabilitation program (treadmill walking three times a week for one hour/visit)
Number of subjects: 20
Study 9112877 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program (instructed to walk at least three times a week, weekly contact for encouragement)
Number of subjects: 20
Study 1555549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pethidine (1 mg kg‐1 of 5% pethidine)
Number of subjects: 0
Study 1555549 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine (3.5 ml of 0.5% plain bupivacaine)
Number of subjects: 0
Study 3979485 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive breathing training
Number of subjects: 27
Study 3979485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inspiratory resistance)
Number of subjects: 27
Study 31020642 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm thick connective tissue graft (CTG)
Number of subjects: 30
Study 31020642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm thick connective tissue graft (CTG)
Number of subjects: 30
Study 28903966 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) followed by conventional medical therapy as required
Number of subjects: 718
Study 28903966 — intervention group
Group type: COMPARATOR
Intervention: Topical medication without laser therapy
Number of subjects: 718
Study 28903966 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 718
Study 28903966 — intervention group
Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 718
Study 25995393 — intervention group
Group type: EXPERIMENTAL
Intervention: Mueller manoeuvre (MM)
Number of subjects: 44
Study 25995393 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiration through a threshold load (ITH)
Number of subjects: 44
Study 25995393 — intervention group
Group type: EXPERIMENTAL
Intervention: End‐expiratory central apnoea (AP)
Number of subjects: 44
Study 25995393 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing (NB)
Number of subjects: 44
Study 24708818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (<100 mmol/day)
Number of subjects: 20
Study 24708818 — intervention group
Group type: COMPARATOR
Intervention: High-sodium intake (additional 120 mmol sodium tablets)
Number of subjects: 20
Study 22607767 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d
Number of subjects: 96
Study 22607767 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg/d
Number of subjects: 96
Study 20518615 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg
Number of subjects: 40
Study 20518615 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 18571083 — intervention group
Group type: EXPERIMENTAL
Intervention: DisCoVisc (hyaluronic acid 1.6%‐chondroitin sulfate 4.0%)
Number of subjects: 100
Study 18571083 — intervention group
Group type: COMPARATOR
Intervention: Viscoat and Provisc (sodium hyaluronate 3.0%‐chondroitin sulfate 4.0% and sodium hyaluronate 1.0%)
Number of subjects: 100
Study 18571083 — intervention group
Group type: EXPERIMENTAL
Intervention: DisCoVisc
Number of subjects: 100
Study 18571083 — intervention group
Group type: COMPARATOR
Intervention: Viscoat and Provisc
Number of subjects: 100